Merck's Keytruda Monotherapy May Get Stuck With Small Role In First-line Lung Cancer

As results for KEYNOTE-042 are reported at ASCO, Merck's Roy Baynes says Keytruda plus chemotherapy is the standard of care...

More From BioPortfolio on "Merck's Keytruda Monotherapy May Get Stuck With Small Role In First-line Lung Cancer"